Bank of America Corp DE Sells 84,485 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Bank of America Corp DE cut its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 77.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,423 shares of the company's stock after selling 84,485 shares during the period. Bank of America Corp DE's holdings in Replimune Group were worth $296,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of REPL. Sterling Capital Management LLC boosted its position in Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock worth $26,000 after purchasing an additional 1,655 shares during the last quarter. MetLife Investment Management LLC boosted its position in Replimune Group by 7.2% in the fourth quarter. MetLife Investment Management LLC now owns 37,659 shares of the company's stock worth $456,000 after purchasing an additional 2,525 shares during the last quarter. Algert Global LLC boosted its position in Replimune Group by 7.1% in the fourth quarter. Algert Global LLC now owns 45,820 shares of the company's stock worth $555,000 after purchasing an additional 3,057 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Replimune Group by 696.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock worth $82,000 after buying an additional 5,922 shares during the period. Finally, Rhumbline Advisers raised its stake in shares of Replimune Group by 8.3% in the fourth quarter. Rhumbline Advisers now owns 95,465 shares of the company's stock worth $1,156,000 after buying an additional 7,317 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Replimune Group

In other news, Director Philip Astley-Sparke sold 32,279 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $260,168.74. Following the transaction, the director now owns 1,405,071 shares of the company's stock, valued at approximately $11,324,872.26. The trade was a 2.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Andrew Schwendenman sold 3,287 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total value of $26,460.35. Following the transaction, the chief accounting officer now directly owns 68,284 shares in the company, valued at approximately $549,686.20. This represents a 4.59% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 74,907 shares of company stock valued at $603,655. 8.80% of the stock is owned by company insiders.

Replimune Group Price Performance

REPL traded down $0.11 on Friday, hitting $9.78. 680,187 shares of the company's stock traded hands, compared to its average volume of 904,078. The company's 50 day simple moving average is $8.60 and its 200-day simple moving average is $10.94. The firm has a market cap of $753.91 million, a price-to-earnings ratio of -3.19 and a beta of 0.63. Replimune Group, Inc. has a one year low of $6.44 and a one year high of $17.00. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the prior year, the company earned ($0.25) earnings per share. As a group, research analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on REPL shares. Piper Sandler raised their price objective on Replimune Group from $14.00 to $22.00 and gave the stock an "overweight" rating in a research note on Monday, June 2nd. JPMorgan Chase & Co. raised their price objective on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $20.83.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.